Achieve Life Sciences Inc (ACHV) Stock Price, Quote & News

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washing...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 210 2217

Website: www.achievelifesciences.com

Address:

22722 29th Dr. SE, Suite 100, Bothell, United States

Ehri Nov. 13 at 9:15 PM

$ACHV In Eastern Europe, the drug cytisine has been available over the counter for under $30 for decades. But okay. Don't tell Trump!

1 · Reply

They_Call_Me_Tater_Salad Nov. 13 at 6:36 PM

$ACHV Posted a new article around my read on the SoPharma dispute update (per John Vandermosten of Zacks), and ACHVs pivot to a Chinese production source and investigation of synthetic. Also some discussion on my read around desired pricing from the November 2025 investor deck based on hints they gave there. https://www.reddit.com/r/ACHV_AchieveLS/comments/1ow8xjm/achieve_life_sciences_the_manufacturing_pivot/

1 · Reply

MoneyGroupLLC Nov. 13 at 1:28 PM

Enter: $ACHV Calls Strike Price: $5 Expiry Date: DEC 19 2025 Buy in Price: $0.45 - $0.45 Sell Price: $0.90 Profit : +99% (Turn every $1 into $1.99) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

ChristIsKingg Nov. 12 at 3:34 PM

$ACHV I bet will do the same thing as yesterday. $IBB is still pozitiv today

0 · Reply

MoneyGroupLLC Nov. 12 at 1:14 PM

Enter: $ACHV Calls Strike Price: $5 Expiry Date: DEC 19 2025 Buy in Price: $0.30 - $0.45 Sell Price: $0.43 Profit : +45% (Turn every $1 into $1.45) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

bobtheknob Nov. 12 at 1:44 AM

$ACHV If you’re here until the buyout, none of this noise matters. The biggest catalyst outside of an early buyout offer is the PDUFA on June 20, 2026. If you can’t stomach or sleep through the daily swings, pops, and drops, this stock isn’t for you—go buy your blue chips, index funds, bonds, or precious metals.

1 · Reply

MiguelitoLoveless Nov. 11 at 10:31 PM

$ACHV ate the spread and bought 12/26 calls

0 · Reply

DoofyInvests Nov. 11 at 9:22 PM

$ACHV Lol. The price movement on this stock always baffles me.

3 · Reply

AyemanAyeman Nov. 11 at 7:58 PM

$ACHV

0 · Reply

ChristIsKingg Nov. 11 at 7:06 PM

$ACHV I like the exuberance, starts on deep red and ending on high green :*

0 · Reply

Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:00 AM EST - 8 days ago

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Nov 3, 2025, 8:30 AM EST - 11 days ago

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

Oct 29, 2025, 8:30 AM EDT - 16 days ago

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

Oct 20, 2025, 8:30 AM EDT - 25 days ago

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

Oct 20, 2025, 7:15 AM EDT - 25 days ago

Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion

Oct 17, 2025, 7:30 AM EDT - 4 weeks ago

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Oct 2, 2025, 4:01 PM EDT - 6 weeks ago

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Sep 22, 2025, 8:30 AM EDT - 7 weeks ago

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

Sep 18, 2025, 8:30 AM EDT - 2 months ago

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

Sep 11, 2025, 5:01 PM EDT - 2 months ago

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

Sep 3, 2025, 8:30 AM EDT - 2 months ago

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Sep 2, 2025, 8:30 AM EDT - 2 months ago

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Aug 21, 2025, 2:11 PM EDT - 3 months ago

Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

Aug 8, 2025, 10:12 AM EDT - 3 months ago

Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:30 AM EDT - 3 months ago

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Jul 29, 2025, 8:30 AM EDT - 3 months ago

Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 4 months ago

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025

Jul 7, 2025, 1:55 PM EDT - 4 months ago

Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation

Jun 30, 2025, 7:52 PM EDT - 4 months ago

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities

Jun 26, 2025, 11:43 PM EDT - 5 months ago

Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

Jun 26, 2025, 4:03 PM EDT - 5 months ago

Achieve Life Sciences Announces Proposed Underwritten Public Offering

Jun 26, 2025, 4:02 PM EDT - 5 months ago

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

OMC

Jun 3, 2025, 6:28 PM EDT - 5 months ago

Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk

May 28, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake

May 13, 2025, 12:16 PM EDT - 6 months ago

Achieve Life Sciences, Inc. (ACHV) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 6 months ago

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

May 6, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

Apr 21, 2025, 11:19 AM EDT - 7 months ago

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

Mar 11, 2025, 2:52 PM EDT - 8 months ago

Achieve Life Sciences, Inc. (ACHV) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 8 months ago

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Mar 7, 2025, 8:30 AM EST - 9 months ago

Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference

Mar 6, 2025, 8:30 AM EST - 9 months ago

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

Feb 11, 2025, 8:30 AM EST - 9 months ago

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 10, 2025, 8:30 AM EST - 9 months ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

Jan 10, 2025, 8:30 AM EST - 11 months ago

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

Jan 7, 2025, 8:30 AM EST - 11 months ago

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Jan 6, 2025, 8:30 AM EST - 11 months ago

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Dec 9, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

Dec 3, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Nov 25, 2024, 7:54 AM EST - 1 year ago

Smoking Cessation Pipeline Insight 2024, with Focus on Emerging Drugs Cytisinicline (Achieve Life Sciences), EMB-001(Embera Pharmaceuticals) and SBP-9330 (Camino Pharma)

Nov 9, 2024, 7:32 AM EST - 1 year ago

Achieve Life Sciences, Inc. (ACHV) Q3 2024 Earnings Call Transcript

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline

Oct 1, 2024, 8:45 AM EDT - 1 year ago

Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs

Aug 26, 2024, 4:30 PM EDT - 1 year ago

Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors

Aug 14, 2024, 4:58 AM EDT - 1 year ago

Achieve Life Sciences, Inc. (ACHV) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence

Ehri Nov. 13 at 9:15 PM

$ACHV In Eastern Europe, the drug cytisine has been available over the counter for under $30 for decades. But okay. Don't tell Trump!

1 · Reply

They_Call_Me_Tater_Salad Nov. 13 at 6:36 PM

1 · Reply

MoneyGroupLLC Nov. 13 at 1:28 PM

0 · Reply

ChristIsKingg Nov. 12 at 3:34 PM

$ACHV I bet will do the same thing as yesterday. $IBB is still pozitiv today

0 · Reply

MoneyGroupLLC Nov. 12 at 1:14 PM

0 · Reply

bobtheknob Nov. 12 at 1:44 AM

1 · Reply

MiguelitoLoveless Nov. 11 at 10:31 PM

$ACHV ate the spread and bought 12/26 calls

0 · Reply

DoofyInvests Nov. 11 at 9:22 PM

$ACHV Lol. The price movement on this stock always baffles me.

3 · Reply

AyemanAyeman Nov. 11 at 7:58 PM

$ACHV

0 · Reply

ChristIsKingg Nov. 11 at 7:06 PM

$ACHV I like the exuberance, starts on deep red and ending on high green :*

0 · Reply

Sieppo Nov. 11 at 7:06 PM

$ACHV $IBB (iShares Biotechnology ETF) is up 2.47% today, $XBI (small cap bio ETF) is up 3% today. Looks a bit like sector rotation..

0 · Reply

Sieppo Nov. 11 at 4:21 PM

$ACHV the double bottom:

1 · Reply

Sieppo Nov. 11 at 4:20 PM

$ACHV I had earlier set the first support after the rip at 4.2. Now it seemed to nicely double bottom bounce (pretty exact at 4.26 and 4.27) from around it so added some shares at 4.39. Bio indexes IBB and XBI are also ripping so the correction for Achieve is possibly now done.

2 · Reply

bowlerhatsftw Nov. 11 at 2:57 PM

$ACHV wait til entry zone

1 · Reply

markwall Nov. 11 at 7:10 AM

$ACHV Achieve Corporate presentation November https://d1io3yog0oux5.cloudfront.net/_0b4914be1badf6f36df72ab3e501782d/achievelifesciences/db/946/9693/pdf/ACHV_Corporate+Deck+November+2025.pdf

0 · Reply

markwall Nov. 11 at 7:04 AM

$ACHV Zachs report: https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_11102025_ACHV_Vandermosten.pdf

0 · Reply

emgeko Nov. 10 at 8:23 PM

$ACHV Interesting information in the Zacks report — I don’t think this had been publicly disclosed until now: “Achieve is now sourcing its cytisinicline from a supplier in China who is extracting cytisine from the Thermopsis tree. If Achieve is not able to come to an agreement with Sopharma, it plans to source cytisinicline from China, formulate, tablet and package it at partners in India and France, and then have it shipped to the United States for commercialization.” “…however, we note that Achieve will owe Sopharma a royalty of 6% of sales.”

1 · Reply

Sieppo Nov. 10 at 8:02 PM

$ACHV the market is extremely green today.. Just wondering if some shorts might try to force push this towards gap fill. Volume is half of friday..

1 · Reply